References
- Duez H, Cariou B, Staels B. (2012). DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol 83:823–32
- Fura A, Khanna A, Vyas V, et al. (2009). Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 37:1164–71
- Lim KS, Kim JR, Choi YJ, et al. (2008). Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose – block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study. Clin Ther 30:1817–30
- Lim KS, Cho JY, Kim BH, et al. (2009). Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. Br J Clin Pharmacol 68:883–90
- Noh YH, Lim HS, Jin SJ, et al. (2012). Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug–drug interaction study in healthy male Korean volunteers. Clin Ther 34:1182–94
- Rhee EJ, Lee WY, Yoon KH, et al. (2010). A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes Obes Metab 12:1113–19
- Scheen AJ. (2010). Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12:648–58
- Yang SJ, Min KW, Gupta SK, et al. (2013). A multicenter, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metab 15:410–16